impact factor
logo
 

Clinical aspects

 

UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis


1, 2, 3, 4, 5, 6

 

  1. Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK.
  2. Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK.
  3. Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK.
  4. Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.
  5. Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.
  6. Centre for Rheumatology, Royal Free London and UCL Division of Medicine, London, UK. c.denton@ucl.ac.uk

CER9761
2016 Vol.34, N°5 ,Suppl.100
PI 0106, PF 0109
Clinical aspects

purchase article

PMID: 27749244 [PubMed]

Received: 14/07/2016
Accepted : 29/07/2016
In Press: 29/09/2016
Published: 14/10/2016

Abstract

The UK Scleroderma Study Group developed guidelines on the diagnosis and management of scleroderma renal crisis (SRC) based on best available evidence and clinical experience. SRC is characterised by the acute onset of severe hypertension and acute kidney injury. Current strategies to reduce the associated morbidity and mortality include identifying at risk patients to aid early diagnosis. ACE inhibitor therapy should be lifelong in all patients, regardless of whether they require renal replacement therapy. Patients with SRC may recover renal function up to 3 years after the crisis, most often within 12 to 18 months.

Rheumatology Article